Pfizer’s Not Waiting To Exhale; Firm Takes Action By Terminating Exubera
This article was originally published in The Pink Sheet Daily
Executive Summary
After the inhaled insulin failed to gain traction, Pfizer also has decided to stop funding investment in a second generation device.
You may also be interested in...
For Some, Oral Insulin’s Allure Persists Despite Hurdles
The recent release of preliminary Phase III results for Generex Biotechnology Corp.’s buccal spray Oral-lyn put the challenging, but alluring for a few dogged developers, oral insulin development space back in the spotlight momentarily.
For Some, Oral Insulin’s Allure Persists Despite Hurdles
The recent release of preliminary Phase III results for Generex Biotechnology Corp.’s buccal spray Oral-lyn put the challenging, but alluring for a few dogged developers, oral insulin development space back in the spotlight momentarily.
Novo Nordisk Halts Development Of AERx, Its Phase III Fast-Acting Inhaled Insulin Product
Lilly/Alkermes' AIR and MannKind's Technosphere Insulin System still aim for market where Exubera failed.